AIMM is an antibody company which selects functional antibodies directly from cured cancer patients. We are advancing a lead compound into the clinic (Q4 2020) with the next clinical candidate to be designated in 2020.
Company HQ State:
Company HQ Country:
Main Therapeutic Focus:
Lead Product in Development:
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):